Top Small Cap Stocks Worth Watching – May 23rd
by Doug Wharley · The Cerbat GemCerebras Systems, Akari Therapeutics, and Destiny Tech100 are the three Small Cap stocks to watch today, according to MarketBeat’s stock screener tool. Small cap stocks are shares of companies with relatively small market capitalizations, typically ranging from about $300 million to $2 billion. For stock market investors, they often represent younger or smaller businesses that can offer higher growth potential, but they also tend to come with greater risk and volatility than larger companies. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.
Cerebras Systems (CBRS)
We are building the fastest AI infrastructure in the world. In AI, speed is critical to win. Speed improves user engagement, expands product capabilities, can lower operating costs, and opens new markets. It shortens iteration cycles for engineers, researchers, and professionals across industries, allowing them to be more productive.
Read Our Latest Research Report on CBRS
Akari Therapeutics (AKTX)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Read Our Latest Research Report on AKTX
Destiny Tech100 (DXYZ)
Read Our Latest Research Report on DXYZ
Further Reading
- MarketBeat’s Top Five Stocks to Own in May 2026
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
- MarketBeat Week in Review – 05/18 – 05/22